Prometheus Powers AI With Fuel Made From Air
10.9.2025 15:00:00 CEST | Business Wire | Press Release
Prometheus Fuels today unveiled a world-first demonstration: powering artificial intelligence entirely with fuel made from air and renewable electricity. In the demo video, which can be viewed on the company’s website, the team used e-fuel made at its pilot facility from air and solar electricity to power locally installed AI, fully off-grid and carbon-neutral.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910077325/en/
Prometheus powers AI with fuel made from air and electricity in a world-first demonstration. The fuel, produced at Prometheus' pilot facility from air and solar electrons, was used to power locally installed AI, fully off-grid and carbon-neutral. It is the first time in history that AI has been powered by a liquid e-fuel.
For the first time in history, AI has been powered by a liquid e-fuel, a fuel made entirely from the air and electricity from the sun.
AI is now the fastest-growing power demand in the world. According to the International Energy Agency, electricity demand from data centers is projected to more than double by 2030, with consumption rising at approximately 15% annually, more than four times the pace of overall electricity demand growth globally. Data centers are waiting years for new grid interconnections, utilities are warning of rising electricity costs, and the gap between supply and demand is widening every quarter.
“We’re offering a new source of power for AI,” said Rob McGinnis, founder and CEO of Prometheus. “We can turn the cheapest electricity in the world – solar power in the best locations – into 24/7 low-cost baseload power anywhere it’s needed.”
The solutions to meet AI’s massive power demand being most widely discussed, including new nuclear plants, renewables plus massive transmission build-outs, or long-duration batteries, will not solve this problem. Nuclear takes decades. Transmission projects face long permitting and construction delays. Batteries can store only a few hours of power, and so can’t operate 24/7. None of these solutions can meet the scale or speed AI requires. Increasingly, fossil fuels like natural gas are being offered, but require expensive infrastructure build-outs like new pipelines and storage facilities. These build-outs face costs and delays similar to grid expansion, while locking in fossil fuel use for decades to come.
Prometheus’ approach bypasses these bottlenecks entirely. By combining low-cost solar electricity with CO2 captured directly from air, Prometheus produces liquid e-fuels that can be transported anywhere, stored on-site, and used in existing turbines and generators for high reliability, 24/7, carbon-neutral power, without the need for a grid connection. Prometheus e-fuels cost less than fossil fuels, an important consideration for such energy intensive facilities. Companies looking to build new data centers can plan on this new low-cost source of 24/7 carbon-neutral power. Meanwhile, existing data centers that currently run on natural gas can switch to Prometheus e-fuels and continue to operate with the same standards of reliability and independence. In addition, they’ll be protected from increasing and volatile gas prices. As the only source of new power that can scale in lockstep with AI, Prometheus e-fuels can relieve the strain on residential and commercial consumers, who are already seeing their electricity and gas bills increase as data centers compete with utilities for a dwindling supply of power.
“We can offer data centers a new option that frees them from the grid, and doesn’t require them to commit to decades of fossil fuel use,” added McGinnis. “We’re the best choice for new power as our fuels are low-cost, carbon-neutral, and quick to deploy. The speed at which we can build out production and start delivering fuel for power is faster than any other new option at scale.”
Prometheus fuel production is in operation today. The company’s commercial pilot facility is currently making solar e-methanol with full-scale components. Unlike grid-based solutions, Prometheus projects can be built and running at the gigawatt scale in less than two years, as they don’t need a grid connection and can be sited in remote locations with streamlined permits.
Orders Now Open
By turning intermittent solar power into an easy to ship and store fuel that costs less than fossil fuels, Prometheus delivers firm, carbon-neutral energy that matches AI’s timeline and scale at the right price. Alongside its demo, Prometheus announced it is now taking orders for its AI power fuels. A dedicated webpage outlining the solution and providing contact information is available at: prometheusfuels.ai.
View Demo
Watch the world-first demo of Prometheus Powering AI at: https://bit.ly/prometheus-powers-ai
About Prometheus Fuels
Prometheus is the global leader in fuels made from air and electricity to power AI data centers, factories, ships, vehicles, and aircraft. The company’s patented technology produces carbon-neutral fuels at lower than fossil fuel prices without subsidies. Designed to run off-grid, Prometheus offers an infinitely scalable source of new power, transforming intermittent renewable energy into firm dispatchable 24/7 power, anywhere it is needed. Backed by top-tier investors including Maersk, BMW, and Y Combinator, Prometheus is redefining the future of energy. Learn more at prometheusfuels.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250910077325/en/
Contacts
Nickell Communications
prometheus@nickellcommunications.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom